The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study

Dorothy A Machalek, Andrew E Grulich, Richard J Hillman, Fengyi Jin, David J Templeton, Sepehr N Tabrizi, Suzanne M Garland, Garrett Prestage, Kirsten McCaffery, Kirsten Howard, Winnie Tong, Christopher K Fairley, Jennifer Roberts, Annabelle Farnsworth, I Mary Poynten, SPANC Study Team, Dorothy A Machalek, Andrew E Grulich, Richard J Hillman, Fengyi Jin, David J Templeton, Sepehr N Tabrizi, Suzanne M Garland, Garrett Prestage, Kirsten McCaffery, Kirsten Howard, Winnie Tong, Christopher K Fairley, Jennifer Roberts, Annabelle Farnsworth, I Mary Poynten, SPANC Study Team

Abstract

Background: The incidence of human papillomavirus (HPV)-associated anal cancer is increasing in men who have sex with men (MSM). Screening for the presumed cancer precursor, high-grade anal squamous intraepithelial lesions (HSIL) in a manner analogous to cervical cancer screening has been proposed. Uncertainty remains regarding anal HPV natural history and the role of anal cytology and high-resolution anoscopy (HRA) as screening tests. Well-designed cohort studies are required to address these issues.

Methods/design: The SPANC study is a prospective study of the epidemiology of low-risk and high-risk anal HPV infection and related cytological and histological abnormalities in HIV-negative and HIV-positive homosexual men aged 35 years and over. The study aims to recruit 600 men from community-based settings in Sydney, Australia. There are six study visits over three years. At the first five visits men undergo a digital ano-rectal examination (DARE), an anal "Papanicolaou" (Pap) test for HPV detection, genotyping and anal cytology, followed by HRA and directed biopsy of any visible abnormalities. The men also complete a behavioural questionnaire before each visit. Questions include a detailed history of sexual behaviour, of anal symptoms, possible anal cancer risk factors and validated quality of life and psychosocial questions. Questionnaires are also completed 2 weeks and 3 months following the provision of test results and include questions on participant experience during the procedure and post-procedure symptoms, including pain and bleeding in addition to quality of life/ psychosocial outcomes.

Discussion: Recruitment for the study began in September 2010 and will conclude in mid-2015, with follow up continuing to 2018. Thus far, over 350 men have been recruited from a variety of community-based settings and are broadly representative of the target screening population. The SPANC study is one of only a small number of cohort studies globally to perform HPV, cytology and HRA screening on all participants over multiple time points. The study results will contribute to understanding of the natural history of anal HPV and inform the possible development of guidelines for implementing anal cancer screening programs in this population.

Figures

Figure 1
Figure 1
Study flow at each study visit.

References

    1. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–1636.
    1. Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health. 2012;9(6):504–508.
    1. Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8(4):311–316.
    1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.
    1. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317(16):973–977.
    1. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–280.
    1. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, Kirk GD, D'Souza G, Bosch RJ, Brooks JT. et al.Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–1034.
    1. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–1868.
    1. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH. et al.HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585.
    1. Palefsky J, Berry JM, Jay N. Anal cancer screening. Lancet Oncol. 2012;13(7):e279–e280. author rreply e280.
    1. Macaya A, Munoz-Santos C, Balaguer A, Barbera MJ. Interventions for anal canal intraepithelial neoplasia. Cochrane Database Syst Rev. 2012;12 CD009244.
    1. Brooks JT, Kaplan JE, Masur H. What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV? Top HIV Med. 2009;17(3):109–114.
    1. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN. et al.Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487–500.
    1. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG. 2002;109(4):364–368.
    1. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B, Templeton DJ, Taylor J, Mindel A, Kaldor JM. et al.Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis. 2006;194(5):561–570.
    1. Prestage G, Mao L, Fogarty A, Van de Ven P, Kippax S, Crawford J, Rawstorne P, Kaldor J, Jin F, Grulich A. How has the sexual behaviour of gay men changed since the onset of AIDS: 1986–2003. Aust N Z J Public Health. 2005;29(6):530–535.
    1. Zablotska IB, Prestage G, Grulich AE, Imrie J. Differing trends in sexual risk behaviours in three Australian states: New South Wales, Victoria and Queensland, 1998–2006. Sex Health. 2008;5(2):125–130.
    1. Zablotska IB, Kippax S, Grulich A, Holt M, Prestage G. Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infections. Sex Health. 2011;8(3):272–279.
    1. Zablotska IB, Holt M, Prestage G. Changes in gay men's participation in gay community life: implications for HIV surveillance and research. AIDS Behav. 2012;16(3):669–675.
    1. Banks E, Redman S, Jorm L, Armstrong B, Bauman A, Beard J, Beral V, Byles J, Corbett S, Cumming R. et al.Cohort profile: the 45 and up study. Int J Epidemiol. 2008;37(5):941–947.
    1. Carballo-Dieguez A, Bauermeister JA, Ventuneac A, Dolezal C, Balan I, Remien RH. The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav. 2008;12(6):860–866.
    1. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82(10):1904–1908.
    1. Shinn E, Basen-Engquist K, Le T, Hansis-Diarte A, Bostic D, Martinez-Cross J, Santos A, Follen M. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med. 2004;39(2):404–412.
    1. Wardle J, Pernet A, Stephens D. Psychological consequences of positive results in cervical cancer screening. Psychol Health. 1995;10(3):185–194.
    1. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–218.
    1. Tabrizi SN, Stevens MP, van Leeuwen MT, Vajdic CM, Botes LP, Medley G, Hillman R, Grulich A, Garland SM. Effect of ThinPrep preparation on human papillomavirus detection and genotyping in rectal samples by PCR. J Clin Microbiol. 2009;47(1):227–229.
    1. Palefsky JM. Practising high-resolution anoscopy. Sex Health. 2012;9(6):580–586.
    1. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum. 1997;40(8):919–928.
    1. Tabrizi SN, Stevens M, Chen S, Rudland E, Kornegay JR, Garland SM. Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol. 2005;123(6):896–899.
    1. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods. 2008;147(2):290–296.
    1. Darragh T, Birdsong G, Luff RD, Davey D. In: The Bethesda system for reporting cervical cytology. Solomon DN R, editor. New York: Springer; 2004. Anal-rectal cytology; pp. 169–175.
    1. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH. et al.The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012;16(3):205–242.
    1. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH. et al.The lower anogenital squamous terminology standardization project for hpv-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266–1297.
    1. Oh KY-T, Palefsky J. In: Diagnostic gynecologic and obstetric pathology. Crum CP, Lee KR, editor. Philadelphia: Elsevier Saunders; 2006. Diseases of the anus; pp. 199–227.
    1. Pirog EC, Quint KD, Yantiss RK. P16/CDKN2A and Ki-67 enhance the detection of anal intraepithelial neoplasia and condyloma and correlate with human papillomavirus detection by polymerase chain reaction. Am J Surg Pathol. 2010;34(10):1449–1455.
    1. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119(1):5–19.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere